Tirzepatide’s research programme is useful because it asks several different questions. How much does body weight change? Does diabetes develop less often in a high-risk population? What happens after withdrawal? Can a treatment affect clinical events rather than measurements alone? Those questions belong together, but their answers should not be collapsed into a general promise of better health.
The studies discussed here are randomised human trials. They evaluate controlled pharmaceutical preparations, eligibility criteria and clinical follow-up.
The initial obesity result has a clear population
SURMOUNT-1 randomised 2,539 adults with obesity, or overweight plus a weight-related complication, excluding diabetes. At 72 weeks, mean weight reduction ranged from 15.0% to 20.9% across the studied tirzepatide groups, versus 3.1% with placebo. The highest-group difference using the displayed means is 17.8 percentage points. Gastrointestinal symptoms predominated; adverse-event discontinuation ranged from 4.3% to 7.1%, compared with 2.6% on placebo. The analysis incorporated treatment discontinuation rather than reporting only successful completers. SURMOUNT-1 publication.
A group average is not an individual forecast. It conceals variation in response, tolerability and persistence. Equally, the comparator matters: a placebo-controlled result estimates an effect in that study context, not how much additional benefit would occur against every other available intervention.
Diabetes prevention adds a longer time horizon
The extended SURMOUNT-1 analysis focused on 1,032 participants who also had prediabetes. After 176 weeks, diabetes had been diagnosed in 1.3% of pooled tirzepatide participants and 13.3% of placebo participants, an absolute difference of 12.0 percentage points. After a further 17 weeks off treatment, the figures were 2.4% and 13.7%. Gastrointestinal events remained the main non-COVID adverse events. This supports delayed progression during the observed period; it does not prove permanent protection after treatment ends. Three-year follow-up.
Relative and absolute effects communicate different information. A large relative reduction can coexist with a smaller absolute reduction when baseline risk is low. Here, the observed placebo incidence helps explain the scale of the difference. Those proportions cannot simply be transferred to people without the entry characteristics of the trial.
Maintenance is a separate experiment
SURMOUNT-4 first gave all participants tirzepatide during a 36-week lead-in, then randomised 670 people to continue it or switch to placebo for 52 weeks. From that randomisation point, continued treatment produced a further 5.5% mean reduction, while the withdrawal group gained 14.0%. These percentages use the later baseline, not starting weight. The design shows the effect of continuation versus withdrawal among people reaching randomisation; it is not an unbiased estimate of initial tolerability in every new starter. SURMOUNT-4 publication.
A head-to-head trial improves the comparison
SURMOUNT-5 directly randomised 751 adults without diabetes to tirzepatide or semaglutide. At 72 weeks, average weight reductions were 20.2% and 13.7%, respectively: a 6.5-percentage-point separation. This answers the comparative weight question more directly than matching results from unrelated trials. However, the study was open-label, and it tested particular pharmaceutical regimens in a defined population. Gastrointestinal adverse events were the most common in both groups. A weight advantage is not automatically evidence of superiority for every clinical outcome. SURMOUNT-5 publication.
Clinical events require their own evidence
SUMMIT studied 731 people with obesity and heart failure with preserved ejection fraction. Over a median 104-week follow-up, cardiovascular death or worsening heart failure occurred in 9.9% with tirzepatide and 15.3% with placebo, an observed 5.4-percentage-point difference. The hazard ratio was 0.62. The benefit was driven mainly by fewer worsening-heart-failure events; cardiovascular deaths were too few to establish a mortality advantage. Adverse events caused treatment withdrawal in 6.3% versus 1.4%. SUMMIT publication.
Reading the programme as a whole
The appropriate synthesis is a set of bounded conclusions. Weight reduction has direct trial support. Reduced diabetes incidence has support in the studied prediabetes population and observation period. Maintenance depends on the continuation question being asked. Heart-failure findings apply to a specific clinical syndrome rather than everyone seeking weight loss.
All five trials were funded by the developer. That does not invalidate randomisation, but it makes transparent protocols, predefined endpoints, complete safety reporting and independent scrutiny especially important. A useful reader keeps the participant group, comparison, timescale and outcome visible beside each number. That habit prevents both exaggeration and the opposite mistake of overlooking meaningful evidence because no single study answers everything.
Continue with How to read a clinical trial for a closer look at interpreting research evidence.
Sources and further reading
- SURMOUNT-1: Tirzepatide for obesity — Peer-reviewed randomised human trial; 2022-06-04.
- Tirzepatide for obesity treatment and diabetes prevention — Peer-reviewed randomised human trial follow-up; 2024-11-13.
- SURMOUNT-4 randomised withdrawal trial — Peer-reviewed randomised human trial; 2023-12-11.
- SURMOUNT-5: Tirzepatide compared with semaglutide — Peer-reviewed randomised human trial; 2025-05-11.
- SUMMIT: Tirzepatide in heart failure and obesity — Peer-reviewed randomised human trial; 2024-11-16.
